Introduction: MNNG HOS transforming gene (MET) abnormalities such as amplification and exon 14 mutations may be responsive to targeted therapies. They are prevalent in lung sarcomatoid carcinomas (LSCs) and must be diagnosed as efficiently as possible. Hypothetically, c-MET overexpression by immunohistochemistry (IHC) may prove effective as a screening test for MET abnormalities.
Methods: Tissue samples were obtained from consecutive patients with a resected LSC in four oncologic centers. IHC was performed using the SP44 antibody (Ventana, Tucson, Arizona) and evaluated using the MetMab score and Hscore. Fluorescence in situ hybridization was applied with the dual color probe set from Zytovision (Clinisciences, Nanterre, France). True MET amplification was diagnosed when MET gene copy number was 5 or greater and the ratio between MET gene copy number and chromosome 7 number was greater than 2. All MET exon 14 alterations including those affecting splice sites occurring within splice donor and acceptor sites were detected in the routine molecular testing on genetic platforms.
Results: A total of 81 LSCs were included. Fourteen (17%) exhibited positive IHC using the MetMab score and 15 (18.5%) using the H-score. MET amplification was detected in six tumors (8.5%) and MET exon 14 mutation in five (6%). A weak positive correlation between IHC and fluorescence in situ hybridization was found (r ¼ 0.27, p ¼ 0.0001). IHC sensitivity for MET amplification was 50%, with a specificity of 83%, positive predictive value of 21.4%, and negative predictive value of 94.7%. IHC sensitivity for *Corresponding author.
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Introduction
The MNNG HOS transforming gene (MET) pathway includes the tyrosine kinase receptor c-MET, its ligand, hepatocyte growth factor, as well as downstream pathways involved in tumor growth, cell survival, invasion, and cell migration. 1 MET pathway activation involves different mechanisms, such as amplification of the MET gene, exon 14 splicing site mutations, activating point mutations, or hepatocyte growth factor-dependent upregulation.
Amplification of the MET gene, characterized by an increased MET gene copy number measured by fluorescence in situ hybridization (FISH), is found in 1% to 4% of NSCLCs. 2 Mutations in MET exon 14 and its flanking introns can induce exon 14 splicing that is thought to cause loss of the intracellular juxta-membrane domain, while increasing c-MET expression at the membrane. The diversity of MET exon 14 alterations, including base substitutions or indels that disrupt the branch point of intron 13, the 3' splice site of intron 13, or the 5' splice site of intron 14, requires improved technologies such as next-generation sequencing (NGS) to cover the whole c.2942-64 to c.3082 þ 42 region. 3 Recently, MET tyrosine kinase inhibitors (TKIs), such as crizotinib and capmatinib, have proven their efficacy on tumors harboring MET mutations or amplifications, suggesting oncogene addiction, therefore rendering MET screening highly relevant. 4, 5 Lung sarcomatoid carcinomas (LSCs) are rare tumors, accounting for less than 3% of all NSCLCs. They are more prevalent among males and smokers and characterized by both high resistance to platinum-based chemotherapy and poor prognosis. 6 A higher frequency of MET exon 14 mutations has been reported in LSCs, with a prevalence ranging between 4.9% and 31.8%. 7, 8 Techniques for the diagnosis of MET amplification and exon 14 mutations are not readily accessible in routine practice. FISH is expensive and time-consuming, whereas NGS panels require sufficient tumor material and high DNA quality, although samples usually are needlebiopsied formalin-fixed paraffin-embedded tumors.
Immunohistochemistry (IHC) could prove effective as a screening test in molecular abnormalities such as ALK receptor tyrosine kinase (ALK) rearrangements. Although FISH remains the gold standard, ALK IHC is highly sensitive (100%), FISH being only performed in ambiguous IHC cases. 9 The aim of this study was to compare MET IHC, FISH, and exon 14 mutation detection in a series of LSC to evaluate IHC as a screening test.
Patients and Methods

Patients and Tissue Tumor Collection
Tissue samples were obtained from surgical lung biopsy specimens of all consecutive patients with LSC diagnosed between 2005 and 2012 in four referral thoracic oncology centers. Clinical data and tumor characteristics were recorded as previously described. 8 Each patient signed an informed consent form as required by national guidelines and samples were collected in line with current legislation.
IHC
In brief, c-MET protein expression was assessed by IHC on 3-mm-thick sections of formalin-fixed paraffinembedded tumor samples, using the rabbit monoclonal primary antibody SP44 (Ventana, Tucson, Arizona). The MetMab score was calculated using the method detailed in Table 1 . 10 The H-score was obtained by multiplying the intensity (from 0 to 3) by the percentage of positive cells (from 0% to 100%), thus obtaining a scale ranging between 0 and 300. The H-score positivity threshold was 150. 11 IHC was conducted by a referent pathologist (M.A.).
FISH
MET gene amplification was assessed using the MET/CEP7 dual color probe set from Zytovision (Clinisciences, Nanterre, France), according to the manufacturer's instructions. MET gene amplification was defined as a MET gene copy number 5 or greater and a MET/CEP7 ratio greater than 2, performed by the same referent pathologist. 2 
Molecular Testing for MET Gene Sequence Abnormalities
Overall, 10-mm-thick sections were cut from the paraffin blocks. Tumor enrichment was performed through selection and macrodissection of areas with at least 50% tumor cells. Total DNA was extracted and purified after paraffin removal, as previously described. 8 All MET alterations from c.2942-64 to c.3082 þ 42 affecting exon 14 splice sites that are indels occurring within splice donor and acceptor sites were detected in the routine molecular testing on ISO15189-certified genetic platforms. Mutations analysis methods were previously reported. 8 All tumor samples were tested by a combined strategy of High Resolution Melting (HRM) assay using Lightcycler 480 system (Roche Diagnostics, Florham Park, New Jersey) to screen all gene sequence abnormalities of exon 14 of the MET gene c3082, c3082 þ 1, c3082 þ 2, and c3082 þ 3, confirmed using MassARRAY iPLEX technology (Agena Bioscience, San Diego, California). Samples for which material was available (n ¼ 40) were also tested by NGS using the solid tumor solution by Sophia Genetics (Saint-Sulpice, Switzerland) based on the xGen Lockdown IDT (Integrated DNA Technologies, Skokie, Illinois) probebased capture technology.
Molecular Screening for Other Mutations
Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and tumor suppressor genes (Panel Lungcarta MassARRAY iPLEX genotyping technology [Agena Bioscience]), as previously described. 8 
Statistical Analyses
Continuous variables were expressed as medians with [min, max] intervals. Categorical variables were expressed as percentages. Comparisons between nonparametric continuous variables were conducted via Mann-Whitney test, and those between categorical variables with the chi-squared test, or the Fisher's exact test when n < 5. Correlation between non-normally distributed continuous variables was calculated using Spearman's correlation coefficient. All the tests were two-sided, with results considered significant when p < 0.05. Analyses were performed using GraphPad Prism (GraphPad Software Inc., La Jolla, California).
Results
General Characteristics
Between 2005 and 2012, 81 patients with LSC were included, of whom 60 (74%) were male, and 75 (94%) were smokers ( Table 2 ). The median age was 62 years. At diagnosis, 37 patients (46%) were at stage I-II disease, and 42 (52%) stage III-IV disease. The most common histologic subtype consisted of pleomorphic carcinoma (n ¼ 63, 77.5%). The most commonly detected mutations were KRAS (n ¼ 21, 26%), and EGFR (n ¼ 11, 13.5%). Positive c-MET IHC was observed in 15 (18.5%) tumors using the H-score (median 30 [range, 0-260]), and in 14 (17%) using the MetMab score (median 0 [range, 0-3]). True MET amplification was found in 6 patients (8.5%) and MET exon 14 mutation in 5 (6%). High MET amplification (MET/CEP7 ratio 5) was found in 2 patients. 
Characteristics of Patients
With True MET Amplification (MET Gene Copy Number 5 and Ratio MET/CEP7 > 2) Men represented 100% of patients with MET amplification, versus 71% (n ¼ 46) of patients without amplification (p ¼ 0
Characteristics of Patients With MET Exon 14 Mutations
MET exon 14 mutations were detected in five patients (6%). They were more often women (80% versus 22.5%, p ¼ 0.02). No other significant differences were found according to MET mutation status (Supplementary Table 2 ).
Correlation Between IHC and MET FISH / MET Exon 14 Mutation
In total, 15 patients (18.5%) had a positive IHC using the H-score and 14 (17%) using the MetMab score. Among MET amplifications (n ¼ 6), 3 (50%) had a positive c-MET IHC. No MET exon 14 mutations were associated with MET amplification. One tumor sample of five (20%) with exon 14 mutation exhibited c-METpositive IHC (Fig. 1) .
Among chromosome 7 polysomies (n ¼ 8), one (12.5%) had a positive IHC with no significant association (p ¼ 1.0). Two (25%) had an MET exon 14 mutation (versus 3% MET exon 14 mutations in patients without polysomy) with a significant association (p ¼ 0.02).
The correlation between IHC H-score and FISH proved weakly positive (R coefficient between 0 and 0.5) (MET gene copy number 5 regardless of MET/CEP7 ratio, i.e., including polysomies [ Fig. 2] , then MET gene copy number 5 and MET/CEP7 > 2, i.e., without polysomies [ Fig. 3]) .
Considering FISH as the gold standard for MET amplification, IHC sensitivity was 50%, specificity 83%, positive predictive value 21.4%, and negative predictive value 94.7%. For high MET amplifications, IHC sensitivity was also 50%. IHC sensitivity for MET exon 14 mutations was 20%, with a specificity of 83%, positive predictive value of 7%, and negative predictive value of 94%.
Discussion
In this cohort of surgically resected LSCs, c-MET IHC overexpression, as well as MET amplification and MET exon 14 mutations were analyzed to determine whether IHC could be a screening test for amplification or mutation. Altogether, 14 tumors (17%) had positive c-MET IHC, six had a MET amplification (8.5%), and five a MET exon 14 mutation (6%).
As MET amplification and exon 14 mutations are potential targets for TKIs in NSCLCs, and particularly in LSCs, these abnormalities must be diagnosed as efficiently as possible. 4, 5 In this study, c-MET IHC could not be considered as a screening test either for MET amplification or MET exon 14 mutations, as sensitivity (50% and 20%, respectively) and correlation (r ¼ 0.27) proved poor, with similar results found for MetMab and H-scores. Current data regarding correlation between IHC and MET molecular alterations are discordant. Watermann et al. 12 found a weak correlation (r ¼ 0.06, p > 0.05) between MET IHC and FISH in 214 NSCLC samples. Casadevall et al. 13 showed no association between IHC and FISH in a nonsquamous NSCLC cohort. Conversely, Park et al.
14 reported a significant association between IHC score and MET amplification (p < 0.001) using the chi-squared test on a large series of 316 adenocarcinomas, with neither sensitivity nor correlation reported. Additionally, Tong et al. 3 revealed in 687 NSCLCs a significant association between IHC and amplification, and between IHC and exon 14 mutation (p < 0.001), based on chi-squared test analyses. Nevertheless, the correlation using Spearman's test proved to be weak. Furthermore, whether significant association between IHC and amplification/mutation does exist or not, sensitivity is a better parameter for diagnosis purposes.
For several other molecular abnormalities, such as ALK rearrangement, IHC proves to be an effective screening option. ALK IHC and FISH are highly correlated, with a sensitivity for IHC approaching 100%. 9 FISH is performed only in ambiguous IHC cases. For ROS1 rearrangements, IHC sensitivity compared to FISH is reported close to 100% with a specificity of 97%. 15 As MET exon 14 mutations induce loss of ubiquitination and increased c-MET membrane presence, their lack of association with c-MET overexpression remains to be understood. One explanation is that the oncogenic properties of MET exon 14 mutations involve other mechanisms (loss of serine 985 with increased kinase activity, loss of aspartate 1002 resulting in loss of pro-apoptotic signals). 1 Another explanation is that LSCs have a different genomic background compared to NSCLCs, which might influence these results. Indeed, MET gene abnormalities occur in a context of other oncogenic and tumor suppressive genes abnormalities involving tumor protein p53 (TP53), serine/threonine kinase 11 (LKB1), or EGFR point mutations, or gene copy number variations that can influence the c-MET protein expression.
Regarding MET exon 14 mutation detection, we used a combined technique (HRM þ MassARRAY) for all tumor samples (n ¼ 81). This allows detection of point mutations, and indels that are deleterious with a higher sensitivity than NGS. Nevertheless, the MassARRAY technology can miss some large deletions. Therefore, NGS was performed on tumor samples with sufficient material (n ¼ 40) to increase detection sensitivity. NGS allowed detection of one exon 14 mutation that was not diagnosed by HRM þ MassARRAY, but also that MassARRAY allowed diagnosis of one more exon 14 mutation, undetected by NGS (data not shown).
Few studies focus specifically on LSC. The main cohorts investigating MET pathway abnormalities in LSCs are summed up in Supplementary Table 3 . Discrepancies exist in the prevalence of positive IHC, amplification, or exon 14 mutations between those cohorts. Our results tend to be on the low end of each one of those abnormalities. However, patients with exon 14 mutations and negative IHC exist in other series. These discrepancies can be explained by the small number of positive cases, which also reduces the power of the given sensitivity and specificity values.
Our findings suggest that MET IHC may not be used as a screening tool. MET FISH and molecular biology techniques (NGS, whole exome sequencing, and fragment analysis) are recommended for the detection of amplifications or exon 14 mutations in NSCLC in routine practice.
